GlobeNewswire

Solar Street Lights Illuminate Bujumbura, Burundi

Dela

Solar Pioneer Gigawatt Global Expands its Green Energy Offerings in Africa

  • "By expanding our investments from commercial scale projects to include off-grid additionally, we are positively impacting the lives of millions of people in Burundi and throughout Africa" -  Yosef I. Abramowitz, CEO, Gigawatt Global 

BUJUMBURA, Burundi, July 19, 2017 (GLOBE NEWSWIRE) -- Downtown Bujumbura just got a little brighter, thanks to an innovative partnership between Mayor Freddy MBONIMPA and Gigawatt Global (http://GigawattGlobal.com), a founding member of United States Power Africa's Beyond the Grid program.

[Access multimedia content here:  http://APO.af/ePScuQ/ http://APO.af/xxruhc/ 
http://APO.af/gdfypU/ http://APO.af/Xpw3uh ]

This week solar-powered 'light islands' began appearing in the heavily-trafficked central bus station and nearby marketplace, extending commercial hours and personal safety.  

"The city of Bujumbura is very pleased to be working with Gigawatt Global on this important solar street lighting project," said Mayor Freddy MBONIMPA. "This project will enhance security as well as provide opportunities for economic development to the citizens of Bujumbura. It is the hope and wish of all involved that this project can spread throughout the city, as well as expand to other cities in Burundi within the near future."

Gigawatt Global is now in discussions to scale the solar-powered 'light islands' program throughout the city and in other major Burundian towns. "We are grateful and pleased to work with the city of Bujumbura, and the Honorable Mayor Freddy MBONIMPA to realise this important first step of the solar street lighting project," said Michael Fichtenberg, Managing Director of Gigawatt Global Burundi. "We intend to expand throughout the capital and to other locations as part of our larger program of green electrification in Burundi, with 40 'light islands' planned in the first phase of the program," Fichtenberg continued. "Every country in which we develop commercial scale solar fields will receive additional benefits like these 'light islands' and rural electrification with mini-grids."

Gigawatt Global, which provides 100% financing for its projects, pioneered commercial scale solar power plants in sub-Sahara Africa, launching the first one in Rwanda in 2014, which is currently supplying 6% of the country's generation capacity. Gigawatt Global will complete a 7.5 Mw solar field in the Gitega region of Burundi in the next six months, which will supply 15% of the East African country's generation capacity. Similar projects are currently being developed in 10 African countries, including Liberia and South Sudan, among many others.  

"Over 95% of Burundi's 11 million people lack access to electricity. Gigawatt Global is honoured to play a role in advancing economic and social development through green power in the country," says Josef Abramowitz, CEO of Gigawatt Global. "By expanding our investments from commercial scale projects to include off-grid installations, we are positively impacting the lives of millions of people in Burundi and throughout Africa, and are becoming a leading force in green energy projects across the continent."

The 'light islands' project in Bujumbura is produced by a team that includes local members Patrick NZINTUNGA, Gigawatt Global Regional Coordinator, and Deo HUGERE, Gigawatt Global Engineer. The engineering, procurement, and construction components of this project are being carried out by Asantys System. The pilot program is supported by the Energy & Environmental Partnership (EEP), an initiative of the governments of the United Kingdom, Austria and Finland, and with an impact investment from entrepreneur Alex Goldberg.

"God bless the people of Burundi," says Goldberg. "In Bujumbura, we found a place ripe for innovation and open to economic development."

As part of Gigawatt Global's commitment to additional Corporate Social Responsibility, one of its investors, Mark Gelfand, funded and built the STEM Centre (Science, Technology, Engineering and Math) at the Université Polytechnique de Gitega. 

Distributed by APO on behalf of Gigawatt Global.
Starting in Rwanda and Burundi, Gigawatt Global is a solar and social development enterprise, concerned with empowering Africans. 

About Gigawatt Global: 
Gigawatt Global is a multinational renewable energy company bringing new sources of green power and social development to Africa. Led by a team of seasoned project developers, financiers, impact investors and solar energy experts, the American-owned Dutch company develops, finances, owns and operates renewable energy installations (solar, wind and hydro) across the African continent.

About Power Africa's Beyond the Grid:
The USAID Power Africa Initiative's goal is to enable electricity access by adding 60 million new electricity connections and 30,000 MW of new and cleaner power generation. Power Africa works to bring together technical and legal experts, the private sectors, and governments from around the world to work in partnership to increase the number of people with access to power.

Media contact:
Michael Fichtenberg
Gigawatt Global 
+972 54 976 0092




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Gigawatt Global via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Immunicum AB (publ) Announces Upcoming Investor Events in October and November22.10.2018 16:00Pressmeddelande

Press Release 22 October 2018 Immunicum AB (publ) Announces Upcoming Investor Events in October and November Immunicum AB (publ; IMMU.ST) announced today that the Company will participate in and host investor events in October and November. At all events Carlos de Sousa, CEO of Immunicum, and other members of the management team, will provide a corporate presentation and be available for a question and answer session. BioStock Life Science Summit Date: October 25, 2018 Presentation Time: 18.50 Central European Time Venue: Medicon Village, Scheelevägen 2, Building 302-auditorium, Lund, Sweden Registration Link: https://www.eventbrite.com/e/biostock-life-science-summit-tickets-51114333347 Immunicum Investor Event - Gothenburg Date: October 29, 2018 Presentation Time: 17.30 - 20.00 Central European Time Venue: First Hotel G, Nils Ericsonplatsen, 411 03 Gothenburg, Sweden Immunicum Investor Event - Stockholm Date: October 30, 2018 Presentation Time: 17.30 - 20.00 Central European Time Venu

Immunicum AB (publ) meddelar kommande investerarevent under oktober och november22.10.2018 16:00Pressmeddelande

Pressmeddelande 22 oktober 2018 Immunicum AB (publ) meddelar kommande investerarevent under oktober och november Immunicum AB (publ; IMMU.ST) meddelar i dag att bolaget kommer att anordna och delta i investerarträffar under oktober och november. Vid samtliga event kommer Carlos de Sousa, Immunicums VD, och övriga medlemmar av ledningsgruppen, att hålla en presentation av bolaget och vara tillgängliga för att svara på frågor. BioStock Life Science Summit Datum: 25 oktober 2018 Presentationstid: Kl. 18.50 CET Plats: Medicon Village, Scheelevägen 2, byggnad 302 - hörsalen, Lund Länk för registrering: https://www.eventbrite.com/e/biostock-life-science-summit-tickets-51114333347 Immunicums investerarevent - Göteborg Datum: 29 oktober 2018 Presentationstid: Kl. 17.30 - 20.00 CET Plats: First Hotel G, Nils Ericsonplatsen, 411 03, Göteborg Immunicums investerarevent - Stockholm Datum: 30 oktober 2018 Presentationstid: Kl. 17.30 - 20.00 CET Plats: Ingenjörshuset Citykonferensen, Plan 1, Malmski

Immunicum AB (publ) presenterar prekliniska resultat för ilixadencel i kombination med checkpointhämmare och immunaktiverare på 2018 års ESMO-kongress22.10.2018 12:45Pressmeddelande

Pressmeddelande 22 oktober 2018 Immunicum AB (publ) presenterar prekliniska resultat för ilixadencel i kombination med checkpointhämmare och immunaktiverare på 2018 års ESMO-kongress -- Intratumoral behandling med ilixadencel, en cellbaserad, lagringsbar immunaktiverare, ger en synergistisk antitumöreffekt och förstärker effekten av behandling med anti-PD-1 och anti-CD137 i djurmodeller -- Immunicum AB (publ; IMMU.ST) presenterar under 2018 års ESMO kongress (European Society for Medical Oncology) prekliniska resultat som visar en synergistisk anti-tumöreffekt när bolagets ledande produkt ilixadencel ges i kombination med en checkpointhämmare eller immunaktiverare. Resultaten från studien, som presenteras på en poster, visar att intratumoralt administrerat ilixadencel kan förstärka anti-tumörsvar och överlevnad vid behandling med checkpointhämmare eller immunaktiverare. Detta visar på potentialen hos ilixadencel att bli en komplementerande verkningsmekanism till flera olika framtida im

Immunicum AB (publ) Presents Preclinical Results of Ilixadencel in Combination with Checkpoint Inhibitors and Immune Enhancers at ESMO 201822.10.2018 12:45Pressmeddelande

Press Release 22 October 2018 Immunicum AB (publ) Presents Preclinical Results of Ilixadencel in Combination with Checkpoint Inhibitors and Immune Enhancers at ESMO 2018 -- Intratumoral treatment with ilixadencel, an off-the-shelf cell-based immune primer, provides synergistic anti-tumor effect and enhances efficacy of anti-PD-1 and anti-CD137 treatment in animal model -- Immunicum AB (publ; IMMU.ST) announced today the presentation of preclinical results that showed anti-tumor synergy between its lead product ilixadencel and a checkpoint inhibitor or an immune enhancer in a poster at the European Society for Medical Oncology (ESMO) 2018 Congress. The results of the study highlight the ability of intratumoral ilixadencel to enhance anti-tumor response and survival of systemic checkpoint inhibitors (anti-PD-1) or immune enhancers (anti-CD137/4-1BB). This emphasizes the potential for ilixadencel in multiple future immuno-oncology combination strategies by incorporating complementary mech

Karolinska Development's portfolio company OssDsign announces FDA clearance for Cranioplug22.10.2018 09:00Pressmeddelande

STOCKHOLM, October 22, 2018. Karolinska Development's portfolio company OssDsign announces that its latest product Cranioplug has received 510(k) clearance by the FDA, which allows marketing and sales of the product in US. The implant is the first product of its kind in the US market. Cranioplug is an implant used during neurosurgical procedures. The product is intended to cover and plug holes drilled into the skull during surgery and to reattach cranial bone removed during surgery. Cranioplug resorbs and is replaced with bone during the healing process. Anders Lundqvist, CEO of OssDsign, said: "Receiving clearance for Cranioplug is an important step for OssDsign. This motivates us to increase our presence in the US market and continue to build our US organization throughout 2018 and beyond. The regenerative features of OssDsign's calcium phosphate composition are now getting recognized, and it's our mission to turn them into real benefits for patients, surgeons and hospital systems."

Karolinska Development's portfolio company OssDsign announces FDA clearance for Cranioplug22.10.2018 09:00Pressmeddelande

STOCKHOLM, October 22, 2018. Karolinska Development's portfolio company OssDsign announces that its latest product Cranioplug has received 510(k) clearance by the FDA, which allows marketing and sales of the product in US. The implant is the first product of its kind in the US market. Cranioplug is an implant used during neurosurgical procedures. The product is intended to cover and plug holes drilled into the skull during surgery and to reattach cranial bone removed during surgery. Cranioplug resorbs and is replaced with bone during the healing process. Anders Lundqvist, CEO of OssDsign, said: "Receiving clearance for Cranioplug is an important step for OssDsign. This motivates us to increase our presence in the US market and continue to build our US organization throughout 2018 and beyond. The regenerative features of OssDsign's calcium phosphate composition are now getting recognized, and it's our mission to turn them into real benefits for patients, surgeons and hospital systems."

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum